Syntara Limited · ASX:SNT
Syntara — Shareholder Meeting (November 2024)
31 slides from Syntara's shareholder meeting presentation, Nov 28, 2024
Slide 1: Annual General Meeting
For personal use only Annual General Meeting 28 November 2024
Slide 2: Syntara Board
Syntara Board Significant international pharmaceutical experience For personal use only Dr Kathleen Metters Dr Simon Green Gary Phillips Hashan De Silva Chair Non-Executive Director Chief Executive Officer Non-Executive Director • Former Senior Vice President • Experienced senior global pharma • 30+
Slide 3: Syntara 2024 AGM Agenda
Syntara 2024 AGM Agenda For personal use only 1. Welcome and opening of meeting 2. Address by Board Chair 3. Presentation by CEO 4. Shareholder questions 5. Formal business: i. Financial Report, Directors’ Report and the Auditor’s Report ii. Resolution 1 - Adoption of the Remuneration Report iii. Re
Slide 4: Online question process
Online question process For personal use only To submit a written question: To ask a question verbally: • Select the ‘Q&A' option on the centre Click the 'raise hand' button on the centre bottom toolbar bottom toolbar at the appropriate time. When the presenter prompts you • Type out your question i
Slide 5: Online voting process
Online voting process For personal use only To vote online visit: https://web.lumiagm.com/#/359067989 When the poll is open, select the vote icon To vote, select either For, Against or Abstain You will see a vote confirmation To change or cancel your vote “click here to change your vote” at any time
Slide 6: Address by Board Chair
For personal use only Address by Board Chair Syntara acknowledges the traditional custodians of the lands on which we meet and pay our respects to their Elders past and Dr. Kathleen Metters, Chair present. 28th November 2024
Slide 7: AGM – CEO Report
For personal use only AGM – CEO Report Gary Phillips, CEO 28th November 2024
Slide 8: Forward looking statement
Forward looking statement For personal use only This document contains involve known and unknown forward-looking statements, risks, uncertainties and other including statements factors, many of which are concerning Syntara’s future beyond our control, and which financial position, plans, and may cau
Slide 9: Investment Highlights
Investment Highlights For personal use only Australian-founded clinical Clinical Backed by specialist Focus on first-in-class and Funded to mid-2025 with stage drug developer. stage drug developer. healthcare investors – best-in-class drugs backed near term data to drive 52% institutional. by in hou
Slide 10: Shareholders & cash
Shareholders & cash For personal use only Financial Information (ASX: SNT) Share Price & Volume - YTD Share price – 27 November 2024 $0.048 Price (AUD) Market cap A$65.9m $0.055 Proforma cash balance (30 Sep 2024)1 A$10.4m $0.045 Enterprise value A$55.5m $0.035 $0.025 Note: 1. Proforma cash of $10.4
Slide 11: Syntara is the global leader in lysyl oxidase chemistry and biology
Syntara is the global leader in lysyl oxidase chemistry and biology For personal use only Multi year research program leveraged with extensive scientific collaborations worldwide has delivered three drugs now in phase 1c/2 studies Lysyl oxidases mediate the final stage in fibrosis SNT-5505 in Oncolo
Slide 12: Myelofibrosis
Myelofibrosis A rare type of bone marrow cancer that disrupts the body's normal production of blood cells For personal use only Key Facts Primary Myelofibrosis is Current standard SNT-5505 characterised by a build up of scar of care (SoC): JAK inhibition In contrast to SoC tissue (fibrosis) in bone
Slide 13: PXS-5505 Phase Trial (MF-101)
PXS-5505 Phase 2 Trial (MF-101) monotherapy; Expert review For personal use only • “PXS-5505 continues to show not only an excellent safety profile but also promising clinical activity. The effect on bone marrow fibrosis is particularly exciting for a disease like myelofibrosis, where despite numero
Slide 14: Phase 2a study; SNT-5505 in patients on a stable dose of JAK inhibitor
Phase 2a study; SNT-5505 in patients on a stable dose of JAK inhibitor For personal use only Fastest route to meaningful data with no dose escalation and utilising existing trial infrastructure Study Plan • 19 clinical trial sites Design Treatment Cohort Endpoints • Recruitment started 13 Dec 2023 I
Slide 15: Strong interest in myelofibrosis assets from strategics
Strong interest in myelofibrosis assets from strategics For personal use only Target / Acquiror / / Date of Feb-2024 June-2023 July-2022 Announcement Drug Name Pelabresib Pacritinib Momelotinib Lead Indication / Myelofibrosis Myelofibrosis Myelofibrosis Phase (Successful Phase 3 (Marketed) (FDA File
Slide 16: Potential to deliver near term value
Potential to deliver near term value Pipeline creates multiple opportunities in high value markets For personal use only Anticipated Upcoming Addressable market Drug Candidate Indication Phase Milestones (US$) Interim 6 month data Myelofibrosis Phase 2 ~$1 billion1 December 2024 SNT-5505 Myelodyspla
Slide 17: Shareholder Questions
For personal use only Shareholder Questions Annual General Meeting, 28 November 2024
Slide 18: Formal Business
For personal use only Formal Business Annual General Meeting, 28 November 2024
Slide 19: First Item of Business
First Item of Business Financial Report, Directors’ Report and Auditor’s Report For personal use only No shareholder vote is required. To receive and consider the financial report, directors’ report and the auditor’s report of the Company for the financial year ended 30 June 2024.
Slide 20: Resolution: Adoption of the Remuneration Report
Resolution 1 Adoption of the Remuneration Report For personal use only Ordinary resolution (advisory vote only): “That the remuneration report of the Company for the year ended 30 June 2024 be adopted.”
Slide 21: Resolution: Adoption of the Remuneration Report – proxy votes
Resolution 1 Adoption of the Remuneration Report For personal use only The Company has received: 638,891,300 proxy votes in favour of the resolution; 3,172,205 proxy votes against the resolution; 5,336,800 proxy votes abstaining from the resolution; 6,856,203 proxy votes excluded from voting; 26,529
Slide 22: Resolution: Re-election of Dr Kathleen Metters
Resolution 2 Re-election of Dr Kathleen Metters as a Non-Executive Director For personal use only Ordinary resolution: “That Dr Kathleen Metters , who retires and offers herself for re- election as a director of the Company, be re-elected as a non- executive director of the Company.”
Slide 23: Resolution: Re-election of Dr Kathleen Metters – proxy votes
Resolution 2 Re-election Dr Kathleen Metters as a Non-Executive Director For personal use only The Company has received: 654,165,423 proxy votes in favour of the resolution; 1,834,507 proxy votes against the resolution; 177,786 proxy votes abstaining from the resolution; 0 proxy votes excluded from
Slide 24: Resolution: Grant of Performance Rights to Mr Gary Phillips
Resolution 3 Approval of the grant of Performance Rights to Mr Gary Phillips, Managing Director and Chief Executive Officer For personal use only Ordinary resolution: “That, for the purposes of the ASX Listing Rule 10.14 and for all other purposes, approval is given for the grant of 2,771,000 zero g
Slide 25: Resolution: Performance Rights to Gary Phillips – proxy votes
Resolution 3 Approval of the grant of Performance Rights to Mr Gary Phillips, Managing Director and Chief Executive Officer For personal use only The Company has received: 635,098,107 proxy votes in favour of the resolution; 6,955,981 proxy votes against the resolution; 11,824,318 proxy votes abstai
Slide 26: Resolution: Employee Option Plan/Performance Rights Plan
Resolution 4 Approval of the Company’s Employee Option Plan/ Performance Rights Plan For personal use only Ordinary resolution: “That, for the purpose of Exception 13(b) of ASX Listing Rule 7.2 and for all other purposes, approval is given for the Company’s Employee Option Plan/Performance Rights Pl
Slide 27: Resolution: Employee Option Plan – proxy votes
Resolution 4 Approval of the Company’s Employee Option Plan/ Performance Rights Plan For personal use only The Company has received: 376,369,359 proxy votes in favour of the resolution; 265,692,904 proxy votes against the resolution; 11,816,143 proxy votes abstaining from the resolution; 318,102 pro
Slide 28: Resolution: Appointment of Auditor
Resolution 5 Appointment of Auditor For personal use only Ordinary resolution: “That, subject to the consent of the Australian Securities and Investments Commission to the resignation of PricewaterhouseCoopers as current auditor of the Company, William Buck Audit (Vic) Pty Ltd, having consented in w
Slide 29: Resolution: Appointment of Auditor – proxy votes
Resolution 5 Appointment of Auditor For personal use only The Company has received: 654,608,680 proxy votes in favour of the resolution; 381,533 proxy votes against the resolution; 1,042,922 proxy votes abstaining from the resolution; 0 proxy votes excluded from voting; 24,753,324 proxies able to be
Slide 30: Close of Voting
For personal use only Close of Voting Annual General Meeting, 28 November 2024
Slide 31: Thank you for your participation
For personal use only Thank you for your participation Annual General Meeting, 28 November 2024